Summit: A 3-Part, Phase 2 Study of Bezuclastinib (CGT9486), an Oral, Selective, and Potent KIT D816V Inhibitor, in Adult Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Year: 2022
Type: article
Source: Blood
Institutions: University of Michigan, Humboldt-Universität zu Berlin, Freie Universität Berlin, Charité - Universitätsmedizin Berlin, Dana-Farber Cancer Institute, ARUP Laboratories (United States), Brigham and Women's Hospital, Harvard University, Stanford Medicine, Stanford Cancer Institute, Stanford University, Cogent Biosciences (United States), The University of Texas MD Anderson Cancer Center
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4310127694